Wall Street Zen Downgrades INmune Bio (NASDAQ:INMB) to Sell

INmune Bio (NASDAQ:INMB) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday.

Separately, Weiss Ratings raised shares of INmune Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday. One equities research analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, INmune Bio currently has an average rating of “Moderate Buy”.

INmune Bio Stock Performance

Shares of INMB opened at $1.62 on Friday. The firm has a market cap of $43.06 million, a PE ratio of -0.97 and a beta of 0.97. The firm’s 50 day moving average price is $1.55 and its 200 day moving average price is $1.46. INmune Bio has a twelve month low of $1.09 and a twelve month high of $3.24.

INmune Bio (NASDAQ:INMB) last posted its earnings results on Thursday, May 7th. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.04.

Institutional Investors Weigh In On INmune Bio

A number of large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its holdings in INmune Bio by 3.4% during the third quarter. Vanguard Group Inc. now owns 876,292 shares of the company’s stock valued at $1,814,000 after purchasing an additional 28,541 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of INmune Bio by 6.9% in the second quarter. Geode Capital Management LLC now owns 389,931 shares of the company’s stock worth $901,000 after buying an additional 25,069 shares during the last quarter. State Street Corp lifted its stake in shares of INmune Bio by 22.3% in the fourth quarter. State Street Corp now owns 347,259 shares of the company’s stock worth $542,000 after buying an additional 63,426 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of INmune Bio by 1,042.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 73,097 shares of the company’s stock worth $169,000 after buying an additional 66,700 shares during the period. Finally, XTX Topco Ltd boosted its holdings in shares of INmune Bio by 41.3% during the 4th quarter. XTX Topco Ltd now owns 68,865 shares of the company’s stock worth $107,000 after buying an additional 20,121 shares during the period. Institutional investors own 12.72% of the company’s stock.

INmune Bio Company Profile

INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company’s research and development efforts concentrate on modulating cellular pathways to restore and enhance the body’s natural defenses, particularly in oncology and neurodegenerative conditions.

The company’s lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions.